Sha Tin, Hong Kong Clinical Trials

A listing of Sha Tin, Hong Kong clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 14 clinical trials
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and spartalizumab) in advanced solid tumor patients. After the determination of the maximum tolerated dose / recommended dose for …

KRAS
solid tumor
Novartis Investigative Site
 (5.8 away) Contact site
  • 0 views
  • 01 Jul, 2021
  • +14 other locations
Phase 1/2 Study of the Highly-selective RET Inhibitor Pralsetinib (BLU-667) in Patients With Thyroid Cancer Non-Small Cell Lung Cancer and Other Advanced Solid Tumors

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in patients with medullary thyroid cancer, RET-altered NSCLC and other RET-altered solid tumors.

immunostimulants
primary cancer
solid tumor
advanced solid tumor
metastasis
The Chinese University of Hong Kong
 (4.4 away) Contact site
  • 1632 views
  • 04 Aug, 2021
  • +92 other locations
YQ23 Study in Patients With Critical Limb Ischaemia

This is an early phase study to assess how safe and tolerable is the new study drug YQ23 and to compare the effectiveness of YQ23 against normal saline to treat critical limb ischaemia. The study also aims to understand how it affects the body and an optional substudy to assess …

  • 0 views
  • 09 Jul, 2021
  • 1 location
EUS Guided Portal-systemic Pressure Gradient Measurement

Portal hypertension is characterised by an increased portal pressure gradient (PPG), that is the difference in pressure between the portal vein and the inferior vena cava (IVC). Portal hypertension is a consequence of cirrhosis resulting from chronic hepatitis. Patients with portal hypertension are at risk of developing complications including oesophageal …

Chinese University of Hong Kong
 (5.8 away) Contact site
  • 0 views
  • 27 Jan, 2021
  • 1 location